Fate Therapeutics, Inc. (FATE) stock prices updated...
 

Fate Therapeutics, Inc. stock price

Fate Therapeutics, Inc. latest news:


  • 08/15/2017 15:42:33

    BRIEF-Fate Therapeutics files for mixed shelf of upto $100 mln

    * Fate Therapeutics Inc files for mixed shelf of upto $100 million - SEC filing

  • 08/14/2017 14:27:00

    BRIEF-Fate Therapeutics Q2 ‍net loss per common share $0.23​

    Fate Therapeutics Inc(FATE). * Fate Therapeutics(FATE) reports second quarter 2017 financial results. * Q2 revenue $1.0 million versus I/B/E/S view $937,000. * Fate Therapeutics Inc (FATE) - qtrly ‍net loss per common share, basic and diluted $0.23​. * Q2 earnings per share view $-0.24, revenue view $936600.00 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

  • 07/14/2017 14:26:43

    BRIEF-Fate Therapeutics to amend and restate loan and security agreement

    Fate Therapeutics Inc(FATE). * Fate Therapeutics Inc(FATE) - on July 14, 2017 co entered into first amendment to amended and restated loan and security agreement - SEC filing. * Fate Therapeutics (FATE) - SVB loan amendment amends certain amended and restated loan and security agreement between company and bank, dated as of July 30, 2014. * Fate Therapeutics Inc (FATE) - term loan matures on January 1, 2022.

  • More trends:

    Fauquier Bankshares, Inc.FBSS | FBR & CoFBRC | Federal-Mogul Holdings CorporationFDML | Federated National Holding CompanyFNHC | FEI CompanyFEIC | Female Health Company (The)FHCO | Fenix Parts, Inc.FENX | Fibrocell Science IncFCSC | FibroGen, IncFGEN | Fidelity search Composite Index Tracking StockONEQ |